扶正抑瘤饮及其配伍不同化疗药物对人胃癌细胞增生的抑制作用  

Inhibition of Fuzheng Yiliuyin combined with various chemotherapeutic drugs on human gastric carcinoma cell lines

作　　者：刘昳[1] 王锐[1] 邱根全[1] 孙喜才[1] 

机构地区：[1]西安交通大学第一医院中医科,陕西省西安市710061

出　　处：《世界华人消化杂志》2004年第11期2564-2567,共4页World Chinese Journal of Digestology

摘　　要：目的:研究扶正抑瘤饮及其配伍不同化疗药物后对体外人胃癌细胞的影响.并探讨中药抑制人胃癌细胞增生的可能的作用机制. 方法:取两株人胃癌细胞株SGC-7901、MGC-803细胞, 分别加入中药及其分别配伍不同的化疗药物及方案(包括化疗药物Vp-16,ADM,5-FU,DDP以及化疗方案EAP, EFP),分别采用MTT法观察各组药物作用胃癌细胞24h, 48 h,72 h后对两种胃癌细胞增生的抑制作用.并通过流式细胞仪测定各组药物作用胃癌细胞72 h后的胃癌细胞凋亡率和坏死率.同时通过透射电镜观察中药作用72 h后的胃癌细胞的细胞超微结构的变化. 结果:透射电镜下可以观察到中药引起胃癌细胞发生典型的凋亡细胞形态学的改变.经t检验,结果显示中药与4种化疗药物2种化疗方案联用24,48,72 h后,对两株胃癌细胞均有协同抑制作用,且随着药物作用时间的延长, 其协同抑制作用也增强.中药与ADM联用对人胃癌细胞株SGC-7901,MGC-803的协同抑制作用均为最弱,分别为(55.4±4.8 vs 20.1±5.5,t=2.41,P=0.02<0.05; 50.7±6.4 vs 14.8±2.7 t=2.42,P=0.02<0.05).其中中药与EFP化疗方案联用对SGC-7901细胞株协同抑制作用较强,分别为(79.4±2.8,83.3±4.8,87.5±4.3,t=2.85, P=0.005<0.05).而中药与DDP(70.2±3.5,80.1±3.6, 84.3±7.5,t=2.42,P=0.02<0.05)和与EFP(82.6±7.8, 87.5±3.1,89.9±4.8,t=2.96,P=0.005<0.05)化疗方案联用对MGC-803细胞株的协同抑制作用较强.且中药与DDP和EFP化疗方案联用72 h对MGC-803细胞株的抑瘤率相近且高于其他治疗(P<0.05).中药与不同的化疗药物及方案联用,对不同分化程度的人胃癌细胞株所产生的协同增效作用不同. 结论:扶正抑瘤饮通过诱导细胞凋亡抑制肿瘤细胞的增生,并与化疗药物有协同效果,但与不同药物联用的协同效率和产生协同效果的机制不同.且中药与单药联用的抑瘤率不一定低于与化疗方案联用的抑瘤率.中药与化疗或与化疗方案联用对不同�AIM: To study the inhibitory effects of Fuzheng Yiliuyin (FZYLY) combined with various chemotherapeutic drugs on human gastric carcinoma cell lines. METHODS: Human gastric carcinoma cell lines, namely SGC-7901 and MGC-803, were treated with FZYLY, FZYLY combined with various kinds of chemotherapeutic drugs (including Vp-16, ADM, 5-FU, DDP) and chemotherapeutic scheme (including EAR and EFP) respectively. The inhibitory effects of various drugs on the two cell lines were observed by MTT method at 24h, 48h and 72h. Flow cytometry was used to detect the apoptotic rate of gastric carcinoma cells after 72 h. At the same time, transmission electron microscope was used to observe the ultrastruc tural changes of gastric carcinoma cells. RESULTS: Obvious apoptosis was observed in the gastric carcinoma cells72 h after treated with FZYLY. FZYLY combined with Vp-16, ADM, 5-FU, DDP and EAP and EFP schemes have the synergic inhibitory effects on the two kinds of cell lines, and the inhibitory effects increased with the duration of drug action. FZYLY combined with ADM had the worst synergic inhibitory effects on both SGC-7901 and MGC-803 (55.4±4.8 vs 20.1±5.5, t=2.41, P= 0.02<0. 05; 50.7±6.4 vs 14.8±2.7, t=2.42, P= 0.02<0.05, compared with FZYLY, respectively. FZYLY combined with EFP chemotherapeutic scheme had better inhibitory effects on SGC-7901, and the inhibitory rates were 79.4± 2.8%, 83.3±4.8%, 87.5±4.3% after 24, 48 h and 72 h respectively (t=2.85, P=0.005<0.05 vs FZYLY). The inhibition rates on MGC-803 cells of FZYLY combined with DDP were not significantly different from those of FZYLY combined with EFP scheme after 72 h, but their effects were both better than other groups. The synergic inhibitory effects on various cell lines were different when FZYLY was combined with various drugs. CONCLUSION: FZYLY can induce apoptosis of gastric carcinoma cells. FZYLY has the synergic function with chemo therapeutic drugs, but the efficiency of synergic effects and the mechanism are different. FZYLY combined with one sing

关 键 词：扶正抑瘤饮 配伍 化疗药物 胃癌 细胞增生 抑制作用 

分 类 号：R735.2[医药卫生—肿瘤]